我們已在上線！進一步了解

Precigen

PGEN

市值 US$22.8億

6.38 USD

-0.82

11.39%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

6.46

+0.08

1.25%

1天

-11.39%

5天

-17.89%

1個月

-14.25%

3個月

28.89%

6個月

61.52%

今年迄今

49.07%

1年

82.81%

5年

35.17%

10年

-75.08%

關於： Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

員工： 47

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 66.7%

中性 33.3%

負面 0%

Zacks Investment Research

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

Zacks Investment Research

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

Zacks Investment Research

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?

Zacks Investment Research

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect

Precigen just received an FDA "platform technology designation" for AdenoVerse, something that validates its versatility and accelerates its pipeline. PAPZIMEOS, the first FDA-approved product from AdenoVerse, is now the first-line standard of care for RRP with rapid payer coverage and strong uptake. PGEN targets a $2B peak global sales opportunity, with EMA approval for PAPZIMEOS potentially doubling the addressable market by year-end or early 2027.

Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect

Zacks Investment Research

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®.

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Zacks Investment Research

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

Zacks Investment Research

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

Zacks Investment Research

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

查看新聞排名

價格圖表採用Lightweight Charts™實作